Also found in: Medical.
CARISACombination Assessment of Ranolazine in Stable Angina
References in periodicals archive ?
CV Therapeutics, which sponsored CARISA, has filed with the Food and Drug Administration for marketing approval for ranolazine.
CARISA randomized to ranolazine or placebo 823 chronic stable angina patients who remained symptomatic on amlodipme, atenolol, or diltiazem.
CARISA was designed to assess the pFOX inhibitor's safety and efficacy when used in combination with conventional antianginal agents.